Title

Physiological (TCR-like) regulated lentiviral vectors for the generation

of improved CAR-T cells

María Tristán-Manzano¹*, Noelia Maldonado-Pérez¹*, Pedro Justicia-Lirio^{1,2}, Pilar Muñoz¹, Marina Cortijo-Gutiérrez¹, Kristina Pavlovic^{1,3}, Rosario Jiménez-Moreno³, Sonia Nogueras³, MDolores Carmona³, Sabina Sánchez-Hernández¹, Araceli Aguilar-González^{1,4}, María Castella⁵, Manel Juan⁵, Concepción Marañón¹, Karim Benabdellah¹, Concha Herrera³ and Francisco Martin^{1#}.

¹Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

²LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

³Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Cellular Therapy Unit, Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

⁴Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Campus Cartuja, 18071 Granada, Spain.

⁵Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.

*Share authorship

Corresponding author: Francisco Martin.

Gene and Cell therapy Unit, Department of Genomic Medicine, Pfizer-University of Granada-

Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO),

PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

francisco.martin@genyo.es

Running title: TCR-like LVs for improved CAR-T

1 List of abbreviations

- 2 ATMP: advanced therapy medical product.
- 3 B-ALL: B-acute lymphoblastic leukaemia.
- 4 CAR: Chimeric Antigen Receptor.
- 5 CMV: Cytomegalovirus.
- 6 eGFP: enhanced green fluorescent protein.
- 7 EF1 α : Elongation Factor 1- α
- 8 EMA: European Medicine Agency.
- 9 FDA: Food and Drug administration.
- 10 LVs: Lentiviral vectors.
- 11 LTR: long-terminal repeats
- 12 MSCV: murine stem cells virus
- 13 NTD: non-transduced cells.
- 14 R/R: relapsed/ refractory.
- 15 ScFv: Single chain variable fragment.
- 16 SFFV: Spleen focus forming virus.
- 17 TCR: T cell receptor.
- 18 TCM: T central memory.
- 19 TEF: T effectors.
- 20 TEM: T effectors memory.
- 21 TN/SCM: T naïve/stem cell memory.
- 22 TRAC: T cell receptor (TCR) constant alpha locus
- 23 WAS: Wiskott-Aldrich syndrome.

1 ABSTRACT

2 Background. Chimeric antigen receptor (CAR) T cells directed against CD19 have achieved 3 impressive outcomes for the treatment of relapsed/refractory B lineage lymphoid neoplasms. 4 However, CAR-T therapy still has important limitations due to severe side effects and the lack 5 of efficiency in 40-50% of the patients. Most CARs-T products are generated using retroviral 6 vectors with strong promoters. However, high CAR expression levels can lead to tonic 7 signalling, premature exhaustion and over-stimulation of CAR-T cells, reducing efficacy and 8 increasing side effects. TCR-like expression of the CAR through genome editing resulted in 9 enhanced anti-tumour potency, reducing tonic signalling and improving CAR-T phenotype. In 10 this manuscript, we searched for LVs that mimic the TCR expression pattern as a closer-to-11 clinic alternative for the generation of improved CAR-T cells.

12 Methods. Different LVs containing viral and human promoters were analysed to select those 13 that closely mimic a TCR-like kinetic profile upon T-cell activation. WAS gene proximal 14 promoter-driven LVs (AW-LVs) were selected to express a second generation 4-1BB αCD19 15 CAR (ARI-0001) into T cells to generate AWARI CAR-T cells. TCR-like AWARI and EF1α-16 driven ARI CAR T cells were analysed for in vitro and in vivo killing efficiency using 17 leukaemia and lymphoma cellular models. Tonic signalling, exhaustion markers and phenotype 18 were determined by flow cytometry. Large-scale automated manufacturing of AWARI CAR-T 19 cells was performed in a CliniMACs Prodigy bioreactor.

Results. Our data showed that LVs expressing the transgene through the *WAS* gene proximal promoter mimic very closely the TCR (CD3) expression pattern kinetic upon TCR stimulation or antigen encounter. Compared to EF1 α -driven ARI CAR-T cells, AWARI CAR-T cells exhibited a higher proportion of naïve/stem cell memory T cells with less exhausted phenotype after efficient killing of CD19+ cells both *in vitro* and *in vivo*. AWARI CAR-T cells also showed lower tonic signalling and reduced secretion of pro-inflammatory cytokines and were efficiently manufactured in large-scale GMP-like conditions.

Conclusions. *WAS*-gene-promoter driven LVs can be used to generate physiological 4-1BB CAR-T cell products with lower tonic signalling, improved phenotype and a safer profile. We
 propose the use of TCR-like LVs as an alternative to strong-promoter driven LVs for the
 generation of CAR-T products.

5 Keywords

6 CAR-T; Physiological expression; TCR-like expression; Lentiviral vectors; tonic signalling;
7 Pro-inflammatory cytokines, Exhaustion; CAR silencing; *WAS* gene promoter; Stem Cell
8 Memory T cells.

9

10 BACKGROUND

11 Chimeric antigen receptor (CAR) T cells have become one of the most promising approaches 12 for the treatment of cancer in particular for B lineage lymphoid neoplasms using aCD19-CAR-T 13 cells, as emphasized with four FDA/EMA-approved Advance Therapy Medicinal Products 14 (ATMPs): tisagenlecleucel (Kymriah, Novartis), axicabtageneciloleucel (Yescarta, Kite-Gilead), 15 brexucabtagene autoleucel (Tecartus, Kite-Gilead) and lisocabtagenemaraleucel (Breyanzi, 16 Bristol Myers Squibb). However, in spite of the impressive results of α CD19-CAR-T cells, 17 there are still several aspects that must be improved. Aggressive severe side effects due to CAR-18 T overstimulation, such as cytokine release syndrome (CRS) and neuroinflammation are 19 common among treated patients and can lead to fatal outcomes. Furthermore, sustained 20 complete remissions range from 62% to 42% for patients treated with commercial ATMPs, 21 evidencing much room for improvement¹.

22 Different works have uncovered the importance of controlling CAR expression levels at the 23 surface of the CAR-T cells in order to optimize its therapeutic activity ²⁻⁴. In spite of this, all 24 four approved ATMPs approved and most of those that are been tested in ongoing clinical trials 25 use autologous T cells transduced with retroviral vectors expressing a α CD19-CAR through 26 constitutive, strong promoters such as the human EF1 α and the murine stem cell virus LTR

1 (MSCV). High CARs concentrations on the T cell surface can result in spontaneous clustering of the CARs (independent of the ligand) leading to tonic-signalling⁴⁵. This tonic signalling can 2 3 affect safety (pro-inflammatory cytokines secretion in non-target tissues) and efficacy (premature exhaustion due to continuous proliferation) of CAR-T cells³⁻⁵. Furthermore, high-4 5 density and constitutive CAR presence on the T cell surface can also lead to overstimulation 6 upon antigen recognition that also affect safety (excess of pro-inflammatory cytokine secretion) and efficacy (early exhaustion, apoptosis and loss of $T_{N/SCM}$ phenotype) of the CAR-T cells^{2, 3}. 7 8 In this direction, Eyquem et al. generated CAR-T cells expressing the α CD19-28 ζ CAR through 9 the endogenous T cell receptor constant alpha chain (TRAC) locus using CRISPR/Cas9². In this 10 manuscript, the authors concluded that tight transcriptional regulation of CAR expression, 11 lowering CAR levels upon target binding and recovering 1-3 days later, was critical for optimal 12 CAR-T performance. However, despite the great potential of genome editing tools for 13 therapeutic applications, there are still several technological and safety issues that need to be 14 solved before the approval of genome edited cells as ATMPs.

15 Contrary to genome editing tools, lentiviral vectors (LVs) derived from HIV-1 have already 16 been approved by the FDA and EMA (Kymriah, Breyanzi and Zynteglo). Latest generation LVs are very resistant to transgene silencing 6,7 , and allow the control of the transgene through 17 physiological or drug inducible promoters⁸⁻¹³. We therefore searched for LVs that express 18 19 transgenes on T cells following a TCR expression kinetic. Since the TRAC promoter in human 20 mature T cells is not well defined, we focus in a well-defined promoter that controls the 21 expression of the WASP protein, which is involved in the formation of the immunological synapse and in translating TCR signals to several T cells functions^{14,15}. We reason that WAS-22 promoter driven LVs⁸¹¹¹⁶ could be an interesting option to express CARs due to their moderate 23 24 expression levels and the functional relationship with the TCR. Here we showed that, indeed, 25 WAS-promoter driven LVs partially mimicked the TCR expression kinetic both in eGFP- and 26 CAR-expressing LVs, with a small down-regulation upon stimulation and recovering basal 27 levels in 5-7 days. Based on these data, we generated TCR-like CAR-T cells using LVs and

analysed potential improvements compared to standard CAR-T cells expressing the CAR
 through strong promoters. TCR-like expression of a αCD19-CAR lead to lower tonic signalling
 in the absence of antigen as well as a better response in its presence, with lower exhaustion
 markers, lower proinflammatory cytokine secretion and improved phenotype both *in vitro* and
 in vivo.

6 MATERIALS and METHODS

7 Cell culture

8 Nalm6 (ATCC® CRL-3273), Namalwa (ATCC® CRL-1432), Jurkat (ATCC® TIB-152), HL9 60 (ATCC® CCL-240) and HEK-293T (ATCC® CRL-11268) cells were cultured as described
10 elsewhere. Namalwa and Nalm6 were modified to express enhanced GFP (eGFP) and
11 Nanoluciferase (NanoLuc) using the SELWP, as described previously¹⁷.

12

13 Human samples

14 Primary T cells were isolated from fresh or frozen apheresis products obtained from healthy 15 donors at the Hematology Department of the Hospital Universitario Reina Sofía (Córdoba, 16 Spain). All donors gave their written informed consent and the study was performed according 17 to the guidelines of the local ethics committee and complies with the requirements regarding 18 quality and safety for donation, obtaining, storage, distribution, and preservation of human cells 19 and tissues under the Spanish specific regulation (RD-L 9/2014). Pan-T cells were isolated by 20 negative selection using immunomagnetic beads (Pan T cell Isolation Kit, Miltenyi Biotec) and 21 following MACSExpress Separator (Miltenyi Biotec) or AutoMACs Pro Separator's (Miltenyi 22 Biotec) protocol and cultured in TexMACS (Miltenyi Biotec) supplemented with 20 UI/ml of 23 IL-2 (Miltenyi Biotec). T cells were activated with T Cell TransAct (Miltenyi Biotec).

24 Plasmid constructs

To construct the SELWP vector, a self-inactivated (SIN) LV expressing eGFP and NanoLuc
under the spleen focus-forming virus (SFFV) promoter, an eGFP-P2A-NanoLuc (NanoLuc

sequence obtained from GeneBank accession: JQ437370. Nucleotides 100-616) flanked by
 AscI/SbfI restriction sites was designed and synthesized by Genscript (Genscript USA Inc. NY,
 U.S.A). The eGFP-P2A-NLuc was cloned into the SEWP LV ¹⁸ by standard molecular biology
 techniques to obtain the SELWP.

We used self-inactivated LVs-driven eGFP already available in our laboratory. SE¹⁶, CEWP¹⁰
and EFEWP (our laboratory) driving eGFP under the control of SFFV, cytomegalovirus, and
EF1a promoters, respectively. *WAS*-promoter based LVs: WE-LVs harbours 0.5kb of the *WAS*proximal promoter¹⁶, and the AWE-LVs include 0.5kb of the *WAS* proximal promoter and 0.38
kb of the alternative promoter⁸.

For AWARI LVs generation, the AW promoter were obtained from the AWE ⁸ by ClaI / BamHI
 and inserted into the ARI-0001 plasmid¹⁹, replacing the EF1α promoter.

12 Lentiviral vector production and titration

Lentiviral vectors were generated by co-transfection of HEK-293T cells with the plasmid of interest, the plasmid pCMVDR8.91and the p-MD-G plasmid as previously described¹². LVs were concentrated by ultracentrifugation at 90.000g for 2h at 4°C, resuspended in TexMACs and storaged at -80°C. LVs titters were determined by transducing Jurkat cells with different dilutions of viral supernatant. Percentage of positive cells was determined by flow cytometry and transducing units per ml (TU/ml) were estimated according to the formula: $(10^5 \text{ plated cells} \times \% \text{ of positive cells})]/ml of LV.$

20

21 T cell transduction

Activated primary T cells were transduced with the different LVs at a multiplicity of infection (MOI) of 10 through spinoculation (800 x g for 60 min at 32°C). Media was exchanged after 5 hours of incubation. At 4-6 days after transduction, the percentage of transduced cells was determined by flow cytometry.

1 Expression pattern analysis of LVs on T cells

For T cells transduced with eGFP-LVs, 10^5 T cells were stimulated with TransAct (Miltenvi 2 Biotec) after 10 days of the initial activation for transduction. Similarly, 10⁴ transduced CAR-T 3 cells were stimulated with 10⁴ CD19+ Namalwa-GFP-NLuc cells in order to simulate the 4 CAR/TCR signalling axis in U-bottom 96-wells plates. eGFP or CAR expression was 5 6 determined at different time-points after stimulation. Cells were stained and fixed with 2% PFA 7 prior FACS acquisition. Expression was indicated as the ratio of MeFI of positive population 8 against the MeFI of non-transduced total population. Fold change indicates the ratio of 9 expression or percentage related to those values at 0h.

10 Flow cytometry

11 CAR expression was determined with a biotin-conjugated goat anti-murine Fab SP-longer 12 Spacer IgG (Jackson Immunoresearch) and APC-conjugated streptavidin (ThermoFisher). For 13 human T cell phenotyping the following mAbs were used: CD45RA-PE/FITC (HI-100), 14 CD62L-PE-Cy7 (DREG56), CD3-PerCP-Cy5/APC-780 (OKT3), PD1-APC (MIH4), LAG-3-15 PE (3DS223H), TIM-3-APC-Cy7 (F38-2E2) all from eBioscience (ThermoFisher). Tonic 16 signalling was determined by intracellular staining with pCD3z-PE (Tyr142, 3ZBR4S) and Fix 17 & Perm Kit (Nordic Bio). Samples were acquired on a FACSCantoII cytometer. FlowJo 18 software (TreeStar) was used for data analysis.

19 Cytokine secretion of CAR-T cells

To analyse cytokine production after T cells stimulation, $5x10^4$ CAR-T cells were co-cultured with Namalwa-GFP target cells at ratio 1:1 in TexMACs without any supplement. Supernatants were collected after 24h and frozen at -80°C. TNF α and IFN \Box were measured with anti-human TFN- α Ready-SET-Go! Kit of Affymetrix (eBioscience) and ELISA MAX Deluxe Set (Biolegend) respectively following manufacturer's instructions.

25

1 Cytotoxicity assay

Target cells (CD19+), such as Namalwa and Nalm-6 cells expressing GFP-Nluc, and non-target
cells (CD19-) HL60 cells (unlabelled), were co-cultured at a concentration of 5x10³ cells per
well in duplicate in 96-well U-bottom plates, and incubated with T cells at various effectortarget (E:T) ratios (0.5:1, 1:1, 2:1) in non-supplemented TexMACs during 16h or 48h as
indicated. Percentage of lysis was determined by flow cytometry related to basal lysis produced
by non-transduced T cells. Specific lysis was determined as follows: 1-(%CD19+ /% HL-60 in
CAR-T cells condition/ %CD19+/%HL-60 in NTD condition) x100.

9 In vivo xenograft animal model and bioluminescence analysis

10 10 to 12-weeks-old NOD/scid-IL-2Rnull (NSG) mice were inoculated intravenously with 3×10^5 11 Namalwa-GFP-NLuc cells per mice, and three days later, mice were randomly infused with CAR-T cells $(5x10^6 \text{ or } 10x10^6)$, non-transduced T cells $(5x10^6 \text{ or } 10x10^6)$ or PBS in the tail's 12 13 vein. Re-challenge was assessed by re-inoculating intravenously a new dose of Namalwa-GFP-Nluc cells. Our experiments are based on a modified randomized block design in which each 14 15 block receives more than one treatment at different periods. Subjects were randomly assigned to 16 receive the different treatments (PBS, T cells or CAR-T cells). This will allow a comparison 17 between the different treatment groups in pairs (each one compared to the control and each one 18 compared to each other). For the estimation of the sample size in each experiment, we 19 calculated the sample size necessary to obtain a $p \ge 0.05$ to be of $n \ge 5$ for controls/CAR-T 20 comparison and an n>8 for AWARI/ARI comparisons based on Mayer et al^{20} . For 21 bioluminescence analysis, furimazine (Nano-Glo, Promega) was diluted at 1/60 in PBS and 22 injected intraperitoneally immediately prior to acquisition on an IVIS Spectrum analyzer 23 (Caliper, Perkin Elmer). Images were acquired during 180s, open field, and analysed using the 24 Living Image 3.2 (Perkin Elmer) or AURA Imaging Software 3.2 (Spectral Instruments 25 Imaging). Mice were sacrificed if experiencing a weight loss greater than 20% or at the 26 indicated days. Samples of blood, bone marrow, liver, spleen and brain were collected. Blood 27 was extracted and diluted 1/5 in EDTA. Cells were obtained from liver and spleen by

mechanical disruption and from bone marrow by the perfusion of both femurs and tibias.
Brain's cells were obtained after Percoll-gradient separation. Percentage of surviving NamalwaGFP-Nluc and T cells (hCD3+) were determined by FACS in the singlet's gate and then in
"human cells" gate, which was previously established after acquiring an artificial mixture of
Namalwa cells and human T cells used as control.

6 GMP-like manufacturing of CAR-T cells on CliniMACs Prodigy

7 Large scale manufacturing of CAR-T cells on CliniMACs Prodigy was carried out under GMP-8 like conditions into Gene-Cell Therapy cleanrooms of Cell Therapy Unit of Hospital 9 Universitario Reina Sofía (Córdoba, Spain). Two different apheresis from a healthy donor was 10 thawed and around 100×10^6 T cells were inoculated into the CliniMACs prodigy bioreactor 11 (Miltenyi Biotec). CD4 and CD8 cells were selected with CD8 and CD4 Reagent (Miltenyi 12 Biotec), cultured with IL-7/IL-15 (Miltenyi Biotec) and activated with αCD3/αCD28 GMP T 13 cell TransAct (Miltenyi Biotec). At day 2 of the process, these cells were transduced with 14 AWARI-LVs (MOI=5). Cells were cultured in TexMACs GMP medium containing GMP-grade 15 IL-15 and IL-7 (Miltenyi Biotec) for 9 or 10 days. Final product was collected with 100ml of 16 NaCl 0.9% + 0.5% human serum albumin (HSA).

Cells were stained with CD3-APC, CD4-FITC, CD8-APC Vio770, CD14-PE Vio770, CD45Vioblue (Miltenyi Biotec). To assess the efficiency of transduction CAR-T cells were stained
with CD-19 Biotin and Anti-biotin PE (Miltenyi Biotec). Viability was tested by using 7AAD
(Miltenyi Biotec). Phenotype was determined with CD45RA-APC (HI100) and CCR7-BV421
(2-L1-A RUO) from BD Pharmingen. Cells were acquired on a MACsQuant cytometer
(Miltenyi Biotec) and analyzed with MACsQuantify Analysis Software (Miltenyi Biotec).

23 Data analysis

Statistical analyses were performed using GraphPad 1.6 software (GraphPad Software Inc., La Jolla, CA). Data were expressed as the mean \pm SEM. Each performed statistical test was

indicated in every figure caption. Survival curves were constructed using the Kaplan–Meier
 method.

3

4 **RESULTS**

5

5 WAS promoter-driven LVs mimic the TCR expression pattern upon T-cell activation

As LVs have already been approved by EMA and the FDA, LVs expressing the CARs with a similar kinetic than the TCR (TCR-like LVs) could be a real alternative to existing LVs to generate more potent and safer CAR-T cells. We first investigated whether *WAS*-promoterdriven LVs could have a more physiological expression pattern compared to current LVs used for CAR-T cells generation. We generated eGFP-expressing LVs particles from two different *WAS*-promoter-driven LVs (**Fig. 1A**, WE and AWE)^{8, 16} and three LVs driven by strong promoters (**Fig. 1A**, CEWP, SE and EFEWP).

13 In order to analyse if the WAS-promoter-driven LVs mimic the TCR expression pattern, we first 14 studied the CD3 expression levels (Fig. 1B and Fig. S1a) of primary human T cells after 15 stimulation with α CD3/ α CD28 nanomatrix and CD19+ cells (in CAR+ cells, Fig 1B and Fig 16 **S1b**) at different time-points. In parallel, T cells transduced with the different eGFP-expressing 17 LVs were stimulated and analysed by flow cytometry as described in Fig. 1A. As it has been reported previously², CD3 expression in T cells decreased soon after stimulation reaching 18 19 minimal expression at 24h/48h at both protein and mRNA levels and recover basal levels after 20 5-7 days (Fig 1B, S1a). Contrary to the CD3 expression pattern, all LVs harbouring 21 constitutive-strong promoters (EF1a (EFEWP), SFFV (SE) and CMV (CEWP)), behaved in an 22 opposite manner, increasing eGFP expression soon after T cell stimulation (Fig. 1C-top panels, 23 **1D** and **1E**-orange line). Interestingly, WAS-promoter driven LVs partially mimicked the TCR 24 expression kinetic, down-regulating eGFP expression upon stimulation that peak at 48h and 25 recover basal levels after 7 days (Fig. 1C-bottom panels, 1E-blue and green lines).

1 We next investigated whether CARs expressed by WAS-promoter driven LVs also followed a 2 TCR-like kinetic. We constructed the AWARI LV (see M&M for details) based on the ARI-0001 LV backbone²¹, a CAR19-BBzz recently approved as ATMP in Spain, which uses the 3 4 A1B6 clone as scFv (Fig. 1F). We then generated ARI and AWARI CAR-T cells using the ARI 5 and AWARI LVs and analysed their CAR expression kinetic upon activation with CD19+ cells 6 (Fig 1G-left,1H and S1B-left) or α CD3/ α CD28 (Fig 1G-right, 1I and S1B-right). Interestingly, 7 AWARI CAR-T cells showed a down-regulation of CAR levels after antigenic stimulation and 8 a recovery after 48h (Fig. 1H, 1I, blue line; Fig. 1G, bottom panel), while ARI CAR-T cells 9 showed a clear increment on CAR levels after T cell activation (Fig. 1H, 1I, green lines, Fig. 10 1G, top panel). A similar behaviour was also observed when using a third generation α CD19-11 CAR-28BBzz (Fig S1C, S1D). Altogether, our results showed that the AW-LVs can be used to 12 generate CAR-T cells expressing the CAR in a TCR-like manner.

13

TCR-like expression of CAR prevents exhaustion and control proinflammatory cytokines secretion upon antigen exposure *in vitro*

We next compared the behaviour of 2nd generation ARI versus AWARI CAR-T cells. First, we 16 17 measured basal levels of exhaustion markers (LAG-3, PD1, Tim3) (Fig. 2A) and tonic 18 signalling (phospho-CD3z) (Fig. 2B) in a CD19-independent context. AWARI CAR-T cells 19 expressed significant lower levels of LAG-3 and Tim3 (and also a trend for PD1) (Fig. 2A) and 20 less phosphorylation of CD3z (Figure 2B). Both CAR-T cells efficiently killed CD19+ Nalm6 21 (B-ALL derived) and Namalwa (Hodgkin's lymphoma derived), without significant differences 22 (Fig. 2C). Interestingly, LAG-3 expression levels were significantly lower in AWARI 23 compared to ARI CAR-T cells after killing Namalwa cells (Fig. 2D, right). In addition, AWARI 24 CAR-T cells secreted lower levels of TNF α and IFN γ compared to ARI cells (Fig. 2E), 25 indicating a more controlled proinflammatory activity. We also observed a tendency of 26 increased stem memory T cells (CD45RA+CD62L+) population in AWARI versus ARI CAR-T 27 cell (but not statically significant, Figs. S2D, S2E). Finally, similar observations were found

- when 3rd generation CARs (CAR19-28BBzz) were expressed with the AW-LVs in terms of
 lower tonic signalling (Fig S2A) and milder IFNγ secretion (Fig. S2B).
- 3

4 AWARI CAR-T cells are as efficient as ARI CAR-T cells eradicating CD19+ tumour cells

5 *in vivo* and maintain a more stem-like phenotype.

6 In vitro cytotoxicity experiments only represent a direct-short term activity of CAR-T cells. We 7 therefore performed a direct comparison of the anti-tumour activity of ARI versus AWARI 8 CAR-T cells in a xenograft mice model of human lymphoma using two different CAR-T doses 9 and a re-challenge after first lymphoma cells clearance (Fig. 3A, See M&M for details). Both 10 CAR-T cells efficiently eliminated Namalwa tumour cells in treated mice with both doses (Figs. 11 **3B, 3C** and **Fig. S3A**). However, a small amount of Namalwa cells (less than <5%) were 12 detected in liver of some ARI-mice and in brain of some AWARI-mice treated with the low 13 dose (Fig. 3C, left panels). Importantly, CAR expression driven by the two vectors was 14 maintained in all the organs after sacrifice (Fig. 3D), even with a second-challenge, when 15 compared to those ex-vivo levels prior to infusion (Fig. S3B), indicating no promoter silencing.

16 After showing the same therapeutic efficacy, we investigated potential differences in CAR-T 17 cell phenotype after tumour clearance. Interestingly, AWARI-CAR-T cells showed a higher 18 proportion of memory (T_{CM:} CD45RA-CD62L+) and stem memory (T_{SCM}: CD45RA+CD62L+) 19 (Fig. 3D) cells in spleen, bone marrow (BM), blood and liver when compared to ARI-treated 20 mice (Fig.3E, 3F). Specially after re-challenge (inner circle, Fig. 3E), T_{SCM} population of 21 AWARI-CAR-T cells was increased in spleen and liver and T_{CM} subset in BM and brain. In 22 order to further characterize the potential differences, we cultured the cells from processed 23 spleens during 48h in vitro with 200 UI/ml of IL-2 in TexMACs medium (Fig. 3G), and we 24 confirmed an increment in T cell memory populations in AWARI-derived spleens (Fig. 3H, 3I) 25 and a tendency to have lower expression of exhaustion markers (PD1+LAG3+) (Fig. 3H, 3J).

26

1 Large-scale semi-automated manufacturing of AWARI CAR-T cells

2 Before translation of AW-LV to ATMP production for clinical applications, it is important to 3 demonstrate their performance for large-scale automated manufacturing. We therefore used 4 laboratory grade AWARI LVs to generate two batches of CAR-T cells (#01 and #02) in the 5 CliniMACs Prodigy Bioreactor (Miltenyi Biotec) under GMP conditions (see M&M). Samples 6 at days 7 and 10 for batch #01, and 6 and 9 days for batch #02 (Fig. 4A) were collected to study 7 CAR expression (Fig. 4B), viability, expansion (Fig 4C), CD4/CD8 ratio (Fig. 4D), phenotype 8 (Fig. 4E), and in vitro lytic activity (Fig. 4F). In both productions processes, cells were 9 efficiently expanded, with more CD4+ than CD8+ CAR+ cells and prominent $T_{N/SCM}$ (CCR7+ 10 CD62L+) subset (44,85 ±0.07%) at day 7 or day 6, that were drastically reduced at final day of 11 the production (16,55 \pm 13.93%), turning into T_{CM} cells but with minimal effector and effector 12 memory populations (Fig. 4E). As described for other CAR-T cell products, lower expansion 13 times rendered more potent AWARI CAR-T cells (Fig. 4F). All these results point out to the 14 AWARI LVs as a valuable tool for a future clinical trial, although improvements in its lentiviral 15 backbone could further increase transduction efficacy in order to lower costs and time of 16 production.

17

Large-scaled manufactured AWARI CAR-T cells products are highly efficient for tumour clearance and maintain good levels of T_{N/SCM} cells *in vivo*.

20 Finally, we performed a detailed analysis of large-scale manufactured AWARI CAR-T cells in 21 terms of their *in vivo* anti-tumour efficacy and their phenotype after isolation from treated mice 22 (Fig. 5) for both #01 (blue dots) and #02 (green dots) CliniMACS batches. Anti-tumour activity 23 of both AWARI CAR-T cells products were analysed in the Namalwa xenograft mice model as 24 depicted in Fig 5A. Survival (Fig. 5B) and tumour progression (Figs. 5C and 5D) were 25 monitored up to 28-30 days post-treatment showing a strong anti-tumour activity of the AWARI 26 CAR-T cells with 100% survival and undetectable tumour cells in treated mice (Figs. 5C, 5D 27 and Fig, S4A). Control PBS and NTD- inoculated mice developed the disease at similar rates

1 and the majority required to be sacrificed for compassionate reasons at days 13-16. At this time 2 point, the stemness of human CAR-T cells of two AWARI-treated mice (Fig. 5F top panel, 3 S4C) in #01 experiment was clearly maintained. New Namalwa cells were inoculated in 4 AWARI -T cells-treated mice and also in new mice ("New PBS"). Re-challenged AWARI-mice 5 remained tumour-free through the duration of the experiment as did the follow-up group. 6 Similar results were observed in both productions (Fig. 5C, 5D, S4A). The percentage of CAR+ 7 cells (Fig 5E) was maintained before (ex-vivo) and after in vivo elimination of Namalwa cells in 8 the xenograf model with a slight increase in some of the organs (Fig. S4b). Importantly, the 9 phenotypic analysis confirmed the presence of a high proportion of T_{SCM}/T_{CM} populations (Fig. 10 5E, 5F, S4D) at the end point of rechallenged and non-rechallenged mice. However, a 11 significant reduction of these populations was observed from day 13 to day 30 (Fig. 5F top 12 panel, S4C). This data confirmed the *in vitro* (Fig. S2) and *in vivo* (Fig. 3) results showing that 13 the expression of the ARI-CAR19-BBzz through a TCR-like promoter (AWARI-CAR-T cells) 14 maintains the proportion of T_{SCM}/T_{CM} CAR-T cells upon antigen encounter.

15

16

1 **DISCUSSION**

2 α CD19 CAR-T cells have achieved impressive therapeutic benefits in R/R B lineage lymphoid 3 neoplasms, leading to the approval of Kymriah, Yescarta, Tecartus and Breyanzi and over 800 4 clinical trials around the globe. Most of these studies have used autologous T cells that are gene 5 modified by retrovirus-based vectors to express the CAR through a strong promoter (often the 6 $EF1\alpha$ or MSCV promoters). However, CAR-T therapy still has important limitations due to 7 severe side effects and the lack of complete cures in 40-62% of the CD19+ lymphomas¹ and most solid tumours^{22,23}. Improvements in CAR structure (scFV, hinge/spacer, costimulatory 8 9 domains, bi-especific or multispecific CARs, etc) T cell composition or combinational therapies have already shown improved results²⁴. New approaches to improve CAR-T efficacy and/or 10 safety include the control of CAR activity and or other molecules¹³ and mechanism to avoid 11 12 immune-reactions against the CAR-T cells²⁵.

There are several evidences indicating that high levels and continuous expression of the CAR 13 can be deleterious for the efficacy and safety of the CAR-T products²⁻⁴. The loss of efficacy 14 comes in part from the early exhaustion and/or apoptosis of the CAR-T cells due to an excess of 15 CAR signalling after antigen encounter²⁶. Strong and unregulated CAR expression also increase 16 tonic signalling in the absence of target antigen⁴ promoting exhaustion^{3, 5}. On the other side, 17 18 safety issues due to CAR overexpression relates to the increased antigen-independent tonic 19 signalling and to over-stimulation of CAR-T cells that generate CRS. Using genome editing 20 technologies, Eyquem et al. demonstrated that TCR-like expression of CARs resulted in lower 21 tonic signalling, reduced CAR-T exhaustion and increased proportion of TSM/TN CAR-T cells, resulting in improved anti-tumour activity². These authors also showed that low expression was 22 23 not enough to achieve optimal CAR-T products, concluding that a down-regulation of the CAR 24 upon antigen encounter was required for optimal CAR-T performance.

In this manuscript we investigated whether LVs can be used to obtain a TCR-like expressionkinetics that could also result in an improved CAR-T cell product. Our search for human

1 promoters that could mimic the TCR expression pattern pointed to the TRAC locus, however, 2 the TRAC promoter in mature human T cells is not well defined. We therefore focus on the 3 WAS gene promoter because WASP protein is only expressed in hematopoietic cells, is involved in the formation of the immunological synapse and acts as an adaptor of TCR signals^{14,15}. We 4 5 have previously developed different WAS-gene based promoters and identified the AW 6 promoter, harbouring fragments from the alternative and proximal promoter, as the best option to express transgenes in hematopoietic cells^{8, 11, 16}. Here we showed that, indeed, WAS-promoter 7 8 driven LVs (AW-LVs) partially mimicked the TCR expression kinetic, with a small down-9 regulation upon stimulation and recovering basal levels in 5-7 days.

10 Based on the ability of AW-LVs to mimic TCR expression pattern on T cells, we investigated 11 whether 4-1BB-CAR-T cells generated with this "physiological" LVs have a better behaviour 12 compared to that generated with LVs harbouring strong or viral promoters. Although in terms of 13 in vitro or in vivo anti-tumour activity we could not detect significant differences with $EF1\alpha$ -14 driven CAR-T cells, AW-CAR-T cells exhibited lower tonic signalling and a better phenotype 15 after efficient killing of CD19+ cells, with reduced secretion of pro-inflammatory cytokines. 16 These data is largely in agreement with the observations of Eyquem et al. using genome editing technologies to express the CAR through the TRAC locus². However, these authors also showed 17 improved *in vivo* anti-tumour activity². The differences in the tumour model (Nalm6 versus 18 19 Namalwa) as well as in the CAR signalling domain (CD28 versus 4-1BB) and scFv (FMC63 20 versus A3B1) could explain the observed differences. Indeed, the potential deleterious effects of CAR over-expression and tonic signalling are highly influenced by the CAR configuration^{2, 4}. 21 22 For instance, replacing CD28 with the 4-1BB costimulatory domain reversed exhaustion in CAR T cells and improved its persistence and therapeutic efficacy²⁷. The good behaviour of 23 $EF1\alpha$ -driven 4-1BB–CARs T cells and the experimental limitations derived by the graft versus 24 25 host disease (GVHD) caused by the administration of the CAR-T cells can explain the absence 26 of increased therapeutic efficacy in our animal models.

In spite of the good behaviour of 4-1BB-CARs, Gomes-Silva et al demonstrated that very high 1 expression levels of 4-1BB–CARs also lead to apoptosis and limit CAR-T cells expansion⁴. The 2 3 same authors also showed that lowering it expression levels by using $EF1\alpha$ -driven LVs instead 4 of LTR-driven \Box -retroviral vector, improved phenotype, expansion potential and therapeutic 5 efficacy. These studies showed that $EF1\alpha$ -driven LVs already generate a good CAR product for 6 some 4-1BB-CARs. Here we show that TCR-like expression can further improve 4-1BB-CAR-7 T products, in particular for the ARI-0001, by maintaining a better phenotype and controlling 8 tonic signalling and pro-inflammatory cytokine secretion.

9 An important aspect to consider in CAR-T cells is the potential side effects due to 10 overstimulation and/or inadequate stimulation. Severe CRS (grades 3 or 4) is an important hallmark in CD19+ that can compromise efficacy and lead to life-threatening conditions^{28,29}. 11 12 Upon tumour cell encounter, CAR-T cells release different pro-inflammatory cytokines such as 13 TNF α , IFN \Box , IL-1 and GM-CSF that leads to macrophage recruitment and activation causing a dangerous cytokine storm involving IL-6 and GM-CSF^{30, 31}. It has also been demonstrated that 14 15 activation of macrophages through CD40/CD40L, CD69 and LAG-3 also contributes to massive activation²⁹. Although CRS can be managed with corticosteroids and anti-IL6R (Tocilizumab), 16 these interventions also block T cell activation compromising CAR-T efficacy ²⁹. In this 17 18 manuscript, we have shown that CAR-T cells generated with AW-LVs exhibit a milder 19 secretion of TNF α and IFN \square after tumour cells encounter. In addition, we noted that LAG-3 20 expression was reduced after Namalwa interaction which suggests that AW-CAR-T cells could 21 lower the risk of CRS.

We finally investigated the feasibility of generating a viable CAR-T cell product for clinical translation. Here, we have demonstrated that it is feasible to generate TCR-like CAR-T cells in a CliniMACs Prodigy, with high cell viability, predominant stem and CM populations and potent *in vitro* and *in vivo* anti-tumour activity. In contrast and consistent with our comparative results, ARI-0001 generated more memory and effector memory population¹⁹, highlighting another potential advantage of AW-CAR-T cells during the manufacturing process. On the other

hand, the efficacy of transduction was lower compared to ARI (~ 18.4% vs ~30.6%), suggesting
 that a future optimization of the AWARI LV backbone could further improve the manufacturing
 process of AW-CAR-T cells.

Taken all together, we propose the use of AW-LVs as an alternative platform for the
manufacturing of CAR-T cells in order to provide better efficacies and/or safety of the final
products. The final benefits of expressing different CARs through the AW promoter will need to
be determined in each case.

8

9 Conclusions

10 In this work we showed that LVs expressing the transgene through the WAS gene proximal 11 promoter mimic very closely the TCR expression pattern kinetic in T cells. 4-1BB-CAR-T cells 12 generated with WAS-promoter-driven LVs (AWARI CAR-T) exhibited a higher proportion of 13 Naïve/Stem Cell Memory T cells, less exhausted phenotype, lower tonic signalling and reduced 14 secretion of pro-inflammatory cytokines compared to EF1-driven ARI CAR-T. Finally, AWARI 15 CAR-T cells were efficiently manufactured in large-scale GMP-like conditions. Altogether, our 16 data showed that the AW-LVs can be used to generate improved, physiological 4-1BB-CAR-T 17 cell products and propose these LVs as efficient tools for the generation of clinical-grade TCR-18 like CAR-T cells.

19

20

DECLARATIONS

21 Ethics approval and consent to participate

All donors from the Haematology Unit of Hospital Reina Sofía, Córdoba (Spain) gave their
written informed consent and the study was performed according to the established guidelines
of in the approved by the Regional Government Junta de Andalucía-Consejeria de Salud (date

1 of approval: 22/02/2019, signed by D^a Cristina Lucía Dávila Fajardo as secretary of the 2 Research Ethics Committee), that comply with the requirements regarding quality and safety for 3 donation, obtaining, storage, distribution, and preservation of human cells and tissues under the 4 Spanish specific regulation (RD 9/2014) and International Conference of Good Clinical 5 Practice. All the experiments involving animals were performed according to a protocol 6 approved by the Institutional Animal Care and Use Committee of the University of Granada 7 (13/12/2016/181) were in accordance with the European Convention for the Protection of 8 Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS # 123) and the 9 specific Spanish law (R.D. 53/2013). Subjects were randomly assigned to receive the different treatments and sample size estimation was calculated based on Mayer et al^{20} . 10

11 Consent for publication

12 All the authors consent the publication of this manuscript.

13 Availability of data and material

All data relevant to the study are included in the article or uploaded as online supplementalinformation. Figures were created with Biorender.com.

16 Competing interests

FMM, MTM, NMP, PM and KB are inventors of a patent for AW promoter for CAR-T cells applications. P.J.L is contractually associated to LentiStem Biotech, a Spin-Off company that has the license of that patent. The rest of the authors declare that the research was conducted in the absence of other commercial or financial relationships that could be construed as a potential conflict of interest.

22 Funding

This study was funded by the Spanish ISCIII Health Research Fund and the European Regional
Development Fund (FEDER) through research grants PI12/01097, PI15/02015, PI18/00337

1 (F.M.), PI18/00330 (K.B.) and PI17/00672 (P.M.); The CECEyU and CSyF of the Junta de 2 Andalucía FEDER/European Cohesion Fund (FSE) for Andalusia provided the following 3 research grants: 2016000073391-TRA, 2016000073332-TRA, PI-57069, PAIDI-Bio326, 4 CARTPI-0001-201 (F.M.), PI-0014-2016 (K.B) and PEER-0286-2019 (P.M.), PE-0223-2018; 5 The Ministerio de Ciencia, Innovación y Universidades (CDTI) to F.M. (00123009 / SNEO-6 20191072). K.B. and C.M held Nicolas Monardes contracts from regional Ministry of Health 7 (#0006/2018 and C2-0002-2019 respectively). M.T.M., N.M.P and A.A.G. are funded by 8 Spanish Ministry of Education and Science through fellowships FPU16/05467, FPU17/02268 9 and FPU17/04327 respectively. P.J.L is funded through an industrial doctorate MCI DIN2018-10 010180 to LentiStem Biotech. P.M is funded by Fundación Andaluza Progreso y Salud. M.C.G 11 is funded by Spanish Ministry of Education and Science through fellowship GJ (PEJ-2018-12 001760-A). MDC is funded by the grant PE-0223-2018 CSyF of the Junta de Andalucia. 13 M.T.M., N.P.M., P.L.J.L., M.C.G. and A.G.G. are PhD students from the Biomedicine 14 Programme of the University of Granada (Spain).

15 Authors' contributions

16 MTM and NMP designed and performed experiments, analysed data and wrote the manuscript. 17 PLJL performed and analysed experiments and critical review of the manuscript. PM 18 contributed to animal experiments. MCG and KP contributed to T cells isolation and revised the 19 manuscript. RJM and SN designed and produced CliniMACs Prodigy large scale CAR-T cells 20 production process. RJM, SN and MDC performed the phenotypic characterization of 21 CliniMACs-derived products. SSH and AAG contributed to AWARI LVs production. MC and 22 MJ provided ARI-0001 LV and critical review. CM provided material and critical review. KB 23 provided funding and critical review. CH provided funding and critical review of the 24 manuscript. FM conceals the project, designed experiments, analysed data, provides the main 25 funding and wrote the manuscript.

26 Acknowledgements

21

- 1 We thank Ana Fernández-Ibáñez for her support with the IVIS Spectrum Analyzer, Nieves
- 2 Álvarez for her help of ELISA assays. We also thank GENYO's supporting units.
- 3
- 4

5	References
-	

- 6
- Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic
 Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol 2020;10:849.
- Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017;543(7643):113-17.
- Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate
 constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015;3(4):356 67.
- Gomes-Silva D, Mukherjee M, Srinivasan M, et al. Tonic 4-1BB Costimulation in Chimeric
 Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep
 2017;21(1):17-26.
- 5. Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol
 Cancer Ther 2018;17(9):1795-815.
- 6. Benabdellah K, Gutierrez-Guerrero A, Cobo M, et al. A chimeric HS4-SAR insulator (IS2)
 that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem
 cells. PLoS ONE 2014;9(1):e84268.
- 7. Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. Science
 2016;353(6304):1101-2.
- 8. Frecha C, Toscano MG, Costa C, et al. Improved lentiviral vectors for Wiskott-Aldrich
 syndrome gene therapy mimic endogenous expression profiles throughout
 haematopoiesis. Gene Ther 2008;15(12):930-41.
- 9. Romero Z, Torres S, Cobo M, et al. A tissue-specific, activation-inducible, lentiviral vector
 regulated by human CD40L proximal promoter sequences. Gene Ther 2011;18(4):364 71.
- Benabdellah K, Cobo M, Munoz P, et al. Development of an all-in-one lentiviral vector
 system based on the original TetR for the easy generation of Tet-ON cell lines. PLoS
 ONE 2011;6(8):e23734.
- 11. Munoz P, Tristan-Manzano M, Sanchez-Gilabert A, et al. WAS Promoter-Driven Lentiviral
 Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic
 Differentiation. Mol Ther Methods Clin Dev 2020;19:220-35.
- Benabdellah K, Munoz P, Cobo M, et al. Lent-On-Plus Lentiviral vectors for conditional
 expression in human stem cells. Sci Rep 2016;6:37289.
- Tristan-Manzano M, Justicia-Lirio P, Maldonado-Perez N, et al. Externally-Controlled
 Systems for Immunotherapy: From Bench to Bedside. Front Immunol 2020;11:2044.
- 41 14. Calvez R, Lafouresse F, De Meester J, et al. The Wiskott-Aldrich syndrome protein permits
 42 assembly of a focused immunological synapse enabling sustained T-cell receptor
 43 signaling. Haematologica 2011;96(10):1415-23.
- 44 15. Cotta-de-Almeida V, Dupre L, Guipouy D, et al. Signal Integration during T Lymphocyte
 45 Activation and Function: Lessons from the Wiskott-Aldrich Syndrome. Front Immunol
 46 2015;6:47.

1 2 3	16. Martin F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005;12(8):715-23.
4	17. Navarro-Marchal SG-L. Carmen: Entrena, Jose-Manuel: Ruiz-Alcala, Gloria: Tristán-
5	Manzano Maria Martín Francisco Pérez-Victoria Ignacio Peula-Garcia Iosé
6	Manuel Marchal Juan A Anti-CD44-conjugated olive oil liquid nanocansules for
7	targeting pancreatic cancer stem cells Biomacromolecules 2021
, 8	18 Demaison C Parsley K Brouns G et al High-level transduction and gene expression in
9	hematopoietic repopulating cells using a human immunodeficiency [correction of
10	imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen
11	focus forming virus promoter. Hum Gene Ther 2002: 13 (7):803-13.
12	19. Castella M. Caballero-Banos M. Ortiz-Maldonado V. et al. Point-Of-Care CAR T-Cell
13	Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From
14	an Academic Phase I Clinical Trial. Front Immunol 2020; 11 :482.
15	20. Mayer B, Stahl V, Kron M. The use of gatekeeping procedures in the statistical planning of
16	animal experiments. Altern Lab Anim 2017;45(6):317-28.
17	21. Castella M, Boronat A, Martin-Ibanez R, et al. Development of a Novel Anti-CD19
18	Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at
19	Academic Institutions. Mol Ther Methods Clin Dev 2019;12:134-44.
20	22. Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and
21	opportunities. Stem Cell Res Ther 2021; 12 (1):81.
22	23. Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding,
23	Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol
24	2019; 10 :128.
25	24. Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, et al. CAR-T Cells Hit the Tumor
26	Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol
27	2020; 11 :1109.
28	25. Wagner DL, Fritsche E, Pulsipher MA, et al. Immunogenicity of CAR T cells in cancer
29	therapy. Nat Rev Clin Oncol 2021.
30	26. Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease
31	attributes predict leukemia remission durability. J Clin Invest 2019; 129 (5):2123-32.
32	27. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion
33	induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21 (6):581-90.
34	28. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine
35	Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
36	Biol Blood Marrow Transplant 2019; 25 (4):625-38.
37	29. Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell
38	treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther
39	2020; 5 (1):134.
40	30. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release
41	syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
42	Blood 2019; 133 (/):69/-/09.
43	31. Hao Z, Li R, Meng L, et al. Macrophage, the potential key mediator in CAR-T related CRS.

44 Exp Hematol Oncol 2020;**9**:15.

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells



Authors

María Tristán-Manzano, Noelia Maldonado-Pérez, Pedro Justicia-Lirio, Pilar Muñoz, Marina Cortijo, Kristina Pavlovic, Rosario Jiménez-Moreno, Sonia Nogueras, MDolores Carmona, Sabina Sánchez-Hernández, Araceli Aguilar-González, María Castella, Manel Juan, Concepción Marañón, Karim Benabdellah, Inmaculada Herrera and Francisco Martin.

Correspondence

f.martin@genyo.es

In Brief

Current CAR-T cells products use strong promoters to drive CAR expression which lead to high activation, tonic signalling and premature differentiation. Here, we propose the WAS promoter, which drives a partial decrease in CAR expression, as an alternative for the generation of TCR-like CAR-T cells in a LV context with improved characteristics.











FIGURES CAPTION

- 1
- 2

3 Figure 1. T cells transduced with WAS promoter-driven LVs mimic the TCR expression 4 pattern. A) Top: Timeline of the experiments to study eGFP expression pattern after TCR/CAR 5 stimulation. Bottom: diagrams of the different used eGFP-expressing LVs analyzed. B) Fold change 6 of CD3 expression (% relative to 0h) in WT T cells stimulated with α CD3/ α CD28 and α CD19CAR-T cells stimulated with CD19+ cells. Left: fold change in CD3 expression at different times post-7 8 stimulation. (Data are MeFI± SEM *, indicates p<0,05, 2-way-ANOVA, Bonferroni post-Test. n≥5). 9 Right: Representative histograms showing CD3 expression on WT T cells (left) and aCD19CAR-T 10 cells (right) at different times post-stimulation. C) Representative histograms of eGFP expression 11 driven by strong-promoter driven (CEWP, SE and EFEWP- top panels) and WAS-promoter driven 12 (WE, AWE – bottom panels) LVs at different times post-stimulation. D, E) Graphs showing fold 13 change in eGFP (colored lines) and CD3 (black lines) expression along time after α CD3/ α CD28 14 stimulation of T cells transduced with viral promoter-driven (CEWP, SEWP) (D) or eukaryotic-15 promoters driven (EFEWP, WE and AWE) LVs (E). Fold change is calculated by the following 16 formula: ((MeFI of GFP+ population xh/ MeFI of non-transduced cells xh)/ MeFI of GFP+ 17 population 0h/ MeFI of non-transduced cells 0h). 2-way-ANOVA, Bonferroni post-Test, compared 18 with CD3 pattern: *, p<0.05; **, p<0.01; ***, p<0.001. +++ indicates p<0.001 for SEWP compared 19 to CD3 expression. n=5. F) Diagrams of the EF1a promoter-driven (ARI) and WAS-promoter driven 20 (AWARI) LVs expressing the ARI-0001 CAR (α CD19 A3B1-41BB-CD3 ζ) G) Representative 21 histograms of CAR expression levels on CAR-T cells generated with the ARI (top) or AWARI 22 (bottom) LVs and measured at different time points after activation with CD19+ cells (left) or 23 aCD3/aCD28 (right). H, I) Graphs showing fold change in CAR expression on ARI-CAR-T (green 24 lines) and AWARI-CAR-T (blue lines) cells at different time points after activation with CD19+ 25 cells (H) or $\alpha CD3/\alpha CD28$ (I). Data shows the percentage of CAR+ cells at different time points 26 relative to 0 hours. Man-Whitney test, two tails, ** indicates p<0.01 compared to CD3 and + 27 indicates p<0,05 compared to AWARI-CAR-T cells. $n \ge 5$.

28

Figure 2. TCR-like expression improves CAR-T cells properties in vitro. A) Top: 1 2 Representative histograms of LAG-3, PD1 and Tim3 expression of NTD (non-transduced, 3 gray), ARI (blue) and AWARI (green) CAR-T cells determined 10 days after activation with 4 α CD3/CD28. Bottom: Graphs showing expression levels of LAG-3, PD1 and Tim3 of ARI 5 and AWARI CAR-T cells related to the expression in NTD cells. Data are MeFI \pm SEM. 6 One-tailed Man-Whitney test (4 independent-donors). B) Left: Representative histograms of 7 intracellular phospho-CD3z expression after 10 days post-initial activation of NTD (gray), 8 ARI (blue) and AWARI (green) CAR-T cells. Right: Graph showing pCD3z expression 9 levels of each CAR-T cells related to NTD cells. Represented data is the ratio of pCD3z 10 MeFI of ARI or AWARI CAR-T cells divided by the pCD3z MeFI of NTD cells. One-tailed 11 Man-Whitney test (4 independent-donors, $n\geq 4$). C) Lysis of CD19+ cells (Nalm6 and 12 Namalwa) at different ratios of co-culture with ARI and AWARI-CAR-T cells during 48h. 13 Percentage of lysis is related to NTD-driven non-specific CD19+ lysis (n=5). D) Relative expression levels of LAG-3 on ARI and AWARI CAR-T cells 48h after co-culture with 14 15 Nalm6 (left) or Namalwa (right) cells. Data represents LAG-3MeFI of ARI or AWARI 16 CAR-T cells divided by the LAG-3 MeFI of NTD cells. One-tailed Man-Whitney test ($n \ge 5$). 17 E) Levels of secreted TNF α (left) and IFN \square (right) produced by NTD, ARI and AWARI 18 CAR-T cells after 24h of stimulation with Namalwa at ratio 1:1 and determined by ELISA (4 19 independent-donors, $n \ge 4$).

20

Figure 3. *In vivo* anti-tumor activity and phenotype of ARI and AWARI CAR-T cells. A) Experimental design of *in vivo* antitumor activity and phenotypic studies of 5e6 (purple dots) and a 10e6 (blue dots) of ARI and AWARI CAR-T cells. Re-challenge with new Namalwa is indicated with an arrow at day 16 in the 10e6 dose. Phenotypic analysis was performed after sacrifice at day 13 for 5e6 dose and day 28 for 10e6 dose. B) Tumor bioluminescence (BLI) progression with 5e6 (left) and 10e6 T cells doses (right) at different days post-Namalwa inoculation. C) Percentage of surviving Namalwa-GFP-Nluc cells in

1 bone marrow (BM), spleen, blood, liver and blood determined by FACS after the sacrifice 2 with the low (left panels) and high (right panels) doses. This value is analyzed in "singlets 3 human cells" gate (see M&M). Two-tailed Mann-Whitney test, *, p<0.05; **, p<0.01, and 4 ***, p<0.001. N(mice) of low dose: PBS=3, NTD=3, ARI=3, AWARI=3; and high dose: 5 PBS=2, NTD=3, ARI=8, AWARI=5. D) Representative dot-plots of CAR expression and 6 phenotype of CAR+ cells of gated hCD3 from the spleen of ARI and AWARI mice after 7 sacrifice of the high-dose experiment. E) Graphical representation of proportions of T_N/T_{SCM} 8 (CD62L+CD45RA+) (green), T_{CM} (CD62L+CD45RA-) (blue), T_{EM} (CD62L-CD45RA-) 9 (grey) and T_{EF} (CD62L-CD45RA+) (red) subpopulations in ARI (top) and AWARI (bottom) 10 CAR+ cells in the indicated organs after sacrifice of challenged (outer circle) and re-11 challenged (inner circle) mice. *, p<0.05 when compared the T cells subsets of re-challenged 12 ARI and AWARI treated mice. Mann-Whitney one-tail. ++ and +++ p<0.01 and p<0.001 13 respectively of 2-way ANOVA, Bonferroni post-Test of all the population of the total mice 14 (ARI=8 (3+5R), AWARI=5 (2+3R). F) Percentage of T_N/T_{SCM} and T_{CM} after sacrifice of ARI 15 and AWARI hCD3+CAR+ cells (ARI=8, AWARI=5, Mann-Whitney one-tail. G) Spleen 16 from treated mice were isolated and cells suspensions were cultured with 200 UI/ml of IL-2 in TexMACS medium and 2% P/S during 48h. H) Representative dot-plots of 17 18 CD45RA/CD62L and PD1/LAG3 populations of ARI and AWARI mice. I) Percentage of 19 $hCD3 + T_N/T_{SCM}$ and T_{CM} after 48h of *in-vitro* culture. Two-tailed Mann-Whitney test (N=4). 20 J) Percentage of PD1+LAG3+ cells. One-tailed Mann-Whitney test (N=4).

21

Figure 4. GMP-like large-scale production of AWARI CAR T cells. A) Time-line of the GMP-like batches #01 and #02 of AWARI CAR-T cells in the CliniMACS Prodigy. B) Dotplots of CAR expression at days of sample (7/6) and final product (10/9) for both #01 (left) and #02 (right) batches. C) Data from viability, number of CD3, efficiency of CAR-T cell transduction and number of obtained CAR-T cells. FC= flow cytometry, NC= Neubauer chamber counting. D) Variation of percentage of CD4 and CD8+ cells in CAR- and CAR+ cells

1 at sample (s) and final products (f). Two-tailed Mann-Whitney test. E) Graphical representation 2 of the T cells populations at sample (days 6 or 7) and final products (day 9 or 10). 3 T_N/T_{SCM} =Naïve/stem cell memory (CD45RA+CCR7+), T_{CM} = central memory (CD45RA-CCR7+), T_{FM} = effector memory (CD45RA-CCR7-) and T_{FMRA} = effector memory 4 5 RA+(CD45RA+CCR7-). F) In vitro specific lysis of CD19+ cells Nalm6 (left) and Namalwa 6 (right) CD19+ cells by AWARI CAR-T cells harvested at sample day (black line) and final day 7 (red line) for productions #01 and #02. CAR-T cells products were co-cultured at different 8 ratios during 16h (dashed line) or 48h (continuous line).

- 9
- 10

Figure 5. In vivo anti-tumor activity and phenotype of CliniMACS-produced AWARI-11 12 CAR-T cells after one or two Namalwa challenges. A) Experimental design and time-line of 13 the two experiments with CliniMACS batches #01 and #02. R indicates re-challenge. B) 14 Survival of PBS, NTD or AWARI-inoculated mice of #01 and #02 products. Log-Ranked test. C, D) Representative BLI images of tumor burden measured in #01 (C) and #02 (D) 15 16 experiments at different days post Namalwa inoculation as indicated. In both studies, at day 15 17 (#01) or 13 (#02) respectively, new Namalwa cells were inoculated to AWARI treated mice (re-18 challenge, yellow line) and to control mice ('New PBS'). E) Representative dot-plots of 19 Namalwa/hCD3 presence, CAR+ cells of hCD3 and phenotype of CAR- and CAR+ of NTD 20 cells and AWARI CliniMACS #01 from BM after sacrifice. F) Percentage of T_N/_{SCM}+T_{CM} 21 population in hCD3+CAR+ cells analyzed in different organs from mice with one or two 22 (rechallenge, R) inoculations of Namalwa tumor cells in #01 (left) and #02 (right) CliniMACS 23 batches at final day. Only when CAR+ population was >1%, data was analyzed and included 24 here. N (CliniMACS #01): PBS=3, NTD=5, AWARI=10 (2 sacrificed at day 13, 4 mice with 25 one- and 4 mice with two-challenges. N (CliniMACS #02): PBS=2, NTD=3, AWARI =5 (2+3) re-challenged mice). 2-way-ANOVA, Bonferroni Post Test, *, indicates p<0.05, **, p<0.001, 26 27 ***, p<0.0001.

1

2